Moderate to Severe Crohn’s Disease: 6-Mercaptopurine New First Line Therapy

Abstract

Gastroenterology and Nutrition| March 01 2001 Moderate to Severe Crohn’s Disease: 6-Mercaptopurine New First Line Therapy AAP Grand Rounds (2001) 5 (3): 21–22. https://doi.org/10.1542/gr.5-3-21 Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Twitter LinkedIn Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Moderate to Severe Crohn’s Disease: 6-Mercaptopurine New First Line Therapy. AAP Grand Rounds March 2001; 5 (3): 21–22. https://doi.org/10.1542/gr.5-3-21 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search nav search search input Search input auto suggest search filter All PublicationsAll JournalsAAP Grand RoundsPediatricsHospital PediatricsPediatrics In ReviewNeoReviewsAAP NewsAll AAP Sites Search Advanced Search Topics: 6-mercaptopurine, crohn's disease Source: Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology. 2000;119:895–902. Markowitz et al report their experience with a prospective, multicenter, placebo-controlled trial utilizing 6-Mercaptopurine (6-MP) and placebo for 8 weeks in newly diagnosed, moderate to severe Crohn’s disease (CD) in children. Moderate to severe CD in these patients was defined as Harvey-Bradshaw index ≥ 5, ie, patients felt ill, had diarrhea and moderate abdominal pain, and often had other systemic signs or symptoms of CD. All patients also received prednisone as part of initial therapy. Fifty-five children (13 ± 2 years) were given either 6-MP tablets (1.5 mg/kg/day) or placebo for 8 weeks in conjunction with oral prednisone (40 mg/day). Prednisone was adjusted with a predefined schedule, based upon disease activity and weaned when indicated. Study treatment with 6-MP or... You do not currently have access to this content.